NEWS RELEASE for February 10, 2011 at 8:00AM Eastern Time
 
 Contacts: Kerry McAnistan
  Investor Relations Assistant
  Palomar Medical Technologies, Inc.
  781-993-2411
  ir@palomarmedical.com
 
                     
PALOMAR MEDICAL REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER
 AND FISCAL YEAR 2010

Interest in first of its kind home-use PaloVia Skin Renewing Laserfor the treatment of fine lines
 and wrinkles around the eyes exceeds expectations

 
BURLINGTON, MA (February 10, 2011)…Palomar Medical Technologies, Inc. (NASDAQ: PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, today announced financial results for the fourth quarter and year ended December 31, 2010.  Revenues for the quarter ended December 31, 2010 increased to $16.4 million, as compared to $16.3 million reported in the fourth quarter of 2009.  Product and service revenues were $14.3 million, a 2 percent increase over the $14.0 million reported in the fourth quarter of 2009.  Fourth quarter gross margin from product and service revenues was 61 percent, which was consistent with the fourth quarter of 2009.  Loss before income taxes for the fourth quarter ended December 31, 2010 was $2.4 million, which included a $0.6 million patent litigation expense and a $1.0 million non-cash stock-based compensation expense.  Loss before income taxes for the fourth quarter ended December 31, 2009 was $3.3 million, which included a $0.2 million patent litigation expense and a $4.5 million non-cash stock-based compensation expense.  Approximately $3.5 million of the fourth quarter 2009 non-cash stock-based compensation expense was a one-time expense related to the granting of restricted stock awards.  The Company reported net loss of $2.6 million, or $0.14 per share for the fourth quarter of 2010 and $8.5 million for the fourth quarter of 2009.  The balance sheet continues to be strong with $103.0 million in cash, cash equivalents, short-term investments, and marketable securities with no borrowings.
 

 
Revenues for the year ended December 31, 2010 increased to $63.7 million, as compared to $60.6 million reported in 2009.  Product and service revenues were $53.5 million, a 10 percent increase over the $48.8 million reported in 2009.  For the year ended December 31, 2010, gross margin from product and service revenues was 62 percent compared to 58 percent reported in 2009.  Loss before income taxes for the year ended December 31, 2010 was $8.5 million, which included a $3.5 million patent litigation expense and a $3.8 million non-cash stock-based compensation expense.  Loss before income taxes for the year ended December 31, 2009 was $6.0 million, which included a $0.8 million patent litigation expense and a $7.1 million non-cash stock-based compensation expense.  The Company reported net loss of $8.8 million, or $0.47 per share for the year ended December 31, 2010, and a net loss of $10.5 million, or $0.58 per share for the year ended December 31, 2009.
 
 
Chief Executive Officer Joseph P. Caruso commented, “We are pleased with the growth in product revenue this year as compared to last year.  Prices remained stable and gross margins are in excess of 60%.  We have seen an increase in interest for our products and are working toward a stronger presence internationally.  We believe our diversified portfolio of products and strong balance sheet perfectly positions the company for future growth as the economy begins to strengthen.”
 
 
Mr. Caruso continued, “In late December, we launched our first consumer product, the PaloVia Skin Renewing Laser.  The initial interest in this product and new category is much higher than we anticipated.  Our public relations efforts are paying off and exposure for our product and company continue to grow.  The initial orders of the PaloVia Skin Renewing Laser exceeded our projections and we are increasing our production capabilities to meet demand.  The consumer products category represents a new and exciting opportunity for us to engage the consumer directly and introduce our technology to the masses.  We believe direct access to the consumer provides us with a very large opportunity to establish Palomar in the multi-billion dollar beauty market.  It will also enhance our position in the professional physician’s market with a complementary product offering and help drive new patients to doctor’s offices.”
 
Conference Call: As previously announced, Palomar will conduct a conference call and webcast today at 11:30 AM Eastern Time. Management will discuss financial results and strategic matters. If you would like to participate, please call (877) 415-3181 or listen to the webcast in the About Palomar/Investors section of the Company’s website at www.palomarmedical.com. A webcast replay will also be available.
 
- more -
 

 
 

The following information was filed by Palomar Medical Technologies Inc (PMTI) on Thursday, February 10, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Palomar Medical Technologies Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Palomar Medical Technologies Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account